Research programme: monoclonal antibodies - Adocia

Drug Profile

Research programme: monoclonal antibodies - Adocia

Alternative Names: BioChaperone® mAb

Latest Information Update: 01 Aug 2016

Price : $50

At a glance

  • Originator Adocia
  • Class Monoclonal antibodies
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Unspecified

Most Recent Events

  • 27 Jul 2016 Discontinued for Undefined indication in France (SC) before July 2016 becuase Adocia focusing to only diabetes treatments
  • 22 Jan 2015 Early research is ongoing in France
  • 22 Oct 2012 Early research is ongoing in France
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top